Fuat Dede
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Fuat Dede has a total of 154 co-authors. Here are the top co-authors by number of shared publications:
- Tanju Yusuf Erdil
Department of Nuclear Medicine, Marmara University Pendik Training and Research Hospital, Istanbul, Turkey
15 shared publications Halil Turgut Turoglu
Department of Nuclear Medicine, Marmara University School of Medicine, Istanbul, Turkey
13 shared publications- Tunc Ones
Department of Nuclear Medicine, School of Medicine, Marmara University, 34854 Istanbul, Turkey
10 shared publications Sabahat Inanir
Department of Nuclear Medicine, Marmara University School of Medicine, Istanbul, Turkey
7 shared publicationsTunc Ones
5 shared publicationsMustafa Aras
Marmara University School of Medicine, Department of Nuclear Medicine, Istanbul, Turkey
4 shared publications
Latest Publications
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , e12088
Changes in 18F-FDG-PET/CT tumor metabolism and prediction of pathologic complete response rates after neoadjuvant chemotherapy in hormone-positive breast cancer.
E12088 Background: Neoadjuvant chemotherapy (NAC) by reducing the tumor size provides higher operability and breast conserving surgery rate in locally advanced breast cancer (LABC) with an advantage to evaluate chemotherapy response. The aim of this study was to assess the predictive value of relative changes in standard uptake values (SUVmax) of 18F-FDG-PET/CT for pathologic complete response (pCR) after NAC in hormone-positive breast cancer. Methods: 90 hormone-positive LABC patients treated in Marmara University Pendik Research and Training Hospital Medical Oncology Clinics, Istanbul, Turkey between 2009 and 2015 was screened. Eligibility criteria were receiving histopathological verification of hormone–positive LABC, completed NAC (4-8 cycles) and evaluated for pCR postoperatively, and PET/CT scan was performed before and after NAC (anthracycline and/or taxanes-based plus trastuzumab if necessary). The relative changes of SUVmax both in primary tumor and axilla were determined and assessed for predicting pCR. Fiftyone patients were eligible for this retrospective analysis. Results: The median age was 46 years (26-76). Only 7 out of 51 patients (13.7%) had pCR and 44 (86.3%) patients had residual tumor. There was no significant difference between patients who had > 50% (n = 40) and < 50% (n = 11) SUVmax changes for predicting pCR rates (15% and 18% respectively) (p = 1.00). Four patients in HER-2 positive (n = 20) and 3 patients in HER-2 negative (n = 31) groups achieved pCR resulting in no association between HER-2 positivity and pCR rates (p = 0.296). Difference in Ki67 levels, tumor localization, menopausal status, grade, lymphovascular and perineural invasion were not found to be associated with pCR. Conclusions: SUVmax changes in later cycles of NAC as commonly practiced in oncology clinics was not found to be predictive for pCR in hormone-positive LABC. However, almost 80% of the patients had > 50% decrease in SUVmax and may still have a chance for more conservative surgery and less postoperative morbidity. As a result, 18F-FDG-PET/CT may still have a role to evaluate the tumor response with a need of larger studies and analysis for cost-effectivity .
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , e12088
Changes in 18F-FDG-PET/CT tumor metabolism and prediction of pathologic complete response rates after neoadjuvant chemotherapy in hormone-positive breast cancer.
E12088 Background: Neoadjuvant chemotherapy (NAC) by reducing the tumor size provides higher operability and breast conserving surgery rate in locally advanced breast cancer (LABC) with an advantage to evaluate chemotherapy response. The aim of this study was to assess the predictive value of relative changes in standard uptake values (SUVmax) of 18F-FDG-PET/CT for pathologic complete response (pCR) after NAC in hormone-positive breast cancer. Methods: 90 hormone-positive LABC patients treated in Marmara University Pendik Research and Training Hospital Medical Oncology Clinics, Istanbul, Turkey between 2009 and 2015 was screened. Eligibility criteria were receiving histopathological verification of hormone–positive LABC, completed NAC (4-8 cycles) and evaluated for pCR postoperatively, and PET/CT scan was performed before and after NAC (anthracycline and/or taxanes-based plus trastuzumab if necessary). The relative changes of SUVmax both in primary tumor and axilla were determined and assessed for predicting pCR. Fiftyone patients were eligible for this retrospective analysis. Results: The median age was 46 years (26-76). Only 7 out of 51 patients (13.7%) had pCR and 44 (86.3%) patients had residual tumor. There was no significant difference between patients who had > 50% (n = 40) and < 50% (n = 11) SUVmax changes for predicting pCR rates (15% and 18% respectively) (p = 1.00). Four patients in HER-2 positive (n = 20) and 3 patients in HER-2 negative (n = 31) groups achieved pCR resulting in no association between HER-2 positivity and pCR rates (p = 0.296). Difference in Ki67 levels, tumor localization, menopausal status, grade, lymphovascular and perineural invasion were not found to be associated with pCR. Conclusions: SUVmax changes in later cycles of NAC as commonly practiced in oncology clinics was not found to be predictive for pCR in hormone-positive LABC. However, almost 80% of the patients had > 50% decrease in SUVmax and may still have a chance for more conservative surgery and less postoperative morbidity. As a result, 18F-FDG-PET/CT may still have a role to evaluate the tumor response with a need of larger studies and analysis for cost-effectivity .
- 18 July 2015
- Published by Springer Nature in Annals of Nuclear Medicine
- Vol. 29 (9) , 786-791
Carbon-14 urea breath test: does it work in patients with partial gastric resection?
The diagnostic value of Carbon-14 urea breath test (C-14 UBT) in the detection of Helicobacter pylori (H. pylori) infection in non-operated patients has been proved. However, the efficacy of C-14 UBT in patients with partial gastric resection (PGR) has not been evaluated yet. Herein, the results of the C-14 UBT and H. pylori stool antigen test (HpSAT) in this patient group were compared with the endoscopic findings. Multi-breath samples C-14 UBT and HpSAT were performed in all patients on the same day. Histology was used as a gold standard for testing C-14 UBT and HpSAT diagnostic efficacies. 30 patients (mean age: 54.6 ± 11 year) with PGR were included. The sensitivity and specificity of standard C-14 UBT were 29 and 100 %, respectively. When breath samples were collected at 20th min, and >35 CPM was selected as radioactivity threshold, the sensitivity raised to 86 % without any loss of specificity. The specificity and sensitivity of the HpSAT were 71 and 96 %, respectively. The sensitivity of the standard C-14 UBT was very poor for patients with PGR, and results of HpSAT were superior in this population. Certain modifications are needed if C-14 UBT is to be used in PGR patients.
- 18 July 2015
- Published by Springer Nature in Annals of Nuclear Medicine
- Vol. 29 (9) , 786-791
Carbon-14 urea breath test: does it work in patients with partial gastric resection?
The diagnostic value of Carbon-14 urea breath test (C-14 UBT) in the detection of Helicobacter pylori (H. pylori) infection in non-operated patients has been proved. However, the efficacy of C-14 UBT in patients with partial gastric resection (PGR) has not been evaluated yet. Herein, the results of the C-14 UBT and H. pylori stool antigen test (HpSAT) in this patient group were compared with the endoscopic findings. Multi-breath samples C-14 UBT and HpSAT were performed in all patients on the same day. Histology was used as a gold standard for testing C-14 UBT and HpSAT diagnostic efficacies. 30 patients (mean age: 54.6 ± 11 year) with PGR were included. The sensitivity and specificity of standard C-14 UBT were 29 and 100 %, respectively. When breath samples were collected at 20th min, and >35 CPM was selected as radioactivity threshold, the sensitivity raised to 86 % without any loss of specificity. The specificity and sensitivity of the HpSAT were 71 and 96 %, respectively. The sensitivity of the standard C-14 UBT was very poor for patients with PGR, and results of HpSAT were superior in this population. Certain modifications are needed if C-14 UBT is to be used in PGR patients.
- 1 December 2014
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 39 (12) , 1045-1046
Scrotal Peritoneal Mesothelioma on PET/CT
Although malignant mesothelioma originating from the tunica vaginalis has been reported in the literature, direct invasion of malignant peritoneal mesothelioma to the scrotal cavity has not been described yet. Herein, we presented a diffuse malignant peritoneal mesothelioma extending inferiorly to the scrotum via inguinal canal detected on FDG PET/CT.
- 1 December 2014
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 39 (12) , 1045-1046
Scrotal Peritoneal Mesothelioma on PET/CT
Although malignant mesothelioma originating from the tunica vaginalis has been reported in the literature, direct invasion of malignant peritoneal mesothelioma to the scrotal cavity has not been described yet. Herein, we presented a diffuse malignant peritoneal mesothelioma extending inferiorly to the scrotum via inguinal canal detected on FDG PET/CT.
- 1 September 2014
- Published by Elsevier in Revista Española de Medicina Nuclear e Imagen Molecular
- Vol. 33 (5) , 286-289
Evaluation of physiological FDG uptake in the skeleton in adults: Is it uniformly distributed?
- 1 September 2014
- Published by Elsevier in Revista Española de Medicina Nuclear e Imagen Molecular
- Vol. 33 (5) , 286-289
Evaluation of physiological FDG uptake in the skeleton in adults: Is it uniformly distributed?
- 19 August 2014
- Published by Elsevier in Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)
- Vol. 33 (5) , 286-289
Evaluation of physiological FDG uptake in the skeleton in adults: Is it uniformly distributed?
- 19 August 2014
- Published by Elsevier in Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)
- Vol. 33 (5) , 286-289
Evaluation of physiological FDG uptake in the skeleton in adults: Is it uniformly distributed?
- 1 February 2014
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 39 (2) , 196-197
99mTc-MIBI Emboli in the Lungs Detected on SPECT/CT
Although we are familiar with artifactual, focal pulmonary F-FDG accumulations without an apparent underlying pathologic finding, similar artifact for Tc-MIBI has not been described yet. Herein, we reported incidental detection of Tc-MIBI emboli in the lungs on parathyroid SPECT/CT.
- 1 February 2014
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 39 (2) , 196-197
99mTc-MIBI Emboli in the Lungs Detected on SPECT/CT
Although we are familiar with artifactual, focal pulmonary F-FDG accumulations without an apparent underlying pathologic finding, similar artifact for Tc-MIBI has not been described yet. Herein, we reported incidental detection of Tc-MIBI emboli in the lungs on parathyroid SPECT/CT.
- Open Access
- 5 December 2013
- Published by Galenos Yayinevi in Molecular Imaging and Radionuclide Therapy
- Vol. 22 (3) , 109-112
Is The Value of FDG PET/CT in Evaluating Renal Metastasis Underestimated? A Case Report and Review of The Literature
Contrast-enhanced CT or MRI are used as a gold standard imaging modalities in the detection and characterization of renal masses. On the other hand, the role of FDG PET/CT in evaluating primary or metastatic cancers of the kidney is limited due to the excretion of FDG through urinary tract. We reported the FDG PET/CT of a lung cancer patient with multiple metastases in both kidneys which were missed in previous PET/CT, and underestimated on sequential diagnostic abdominal CT study. None declared.
- 5 December 2013
- Published by Galenos Yayinevi in Molecular Imaging and Radionuclide Therapy
- Vol. 22 (3) , 109-112
Open AccessIs The Value of FDG PET/CT in Evaluating Renal Metastasis Underestimated? A Case Report and Review of The Literature
Contrast-enhanced CT or MRI are used as a gold standard imaging modalities in the detection and characterization of renal masses. On the other hand, the role of FDG PET/CT in evaluating primary or metastatic cancers of the kidney is limited due to the excretion of FDG through urinary tract. We reported the FDG PET/CT of a lung cancer patient with multiple metastases in both kidneys which were missed in previous PET/CT, and underestimated on sequential diagnostic abdominal CT study. None declared.
- 1 January 2013
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 38 (1) , 47-49
FDG PET/CT Appearance of Portal Vein Tumor Thrombus in the Gastric Primitive Neuroectodermal Tumor
Gastric primitive neuroectodermal tumor (PNET) is a very rare tumor. There are only a few case reports in the literature. Although cases with FDG uptake in the portal venous tumor thrombus (PVTT) in different primary malignancies have been evaluated before, the coexistence of PNET and PVTT has not been reported yet. Herein, we report the case of a gastric PNET with PVTT, which resolved after 3 cycles of polychemotherapy except for a residual tumor focus in the gastric corpus.
- 1 January 2013
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 38 (1) , 47-49
FDG PET/CT Appearance of Portal Vein Tumor Thrombus in the Gastric Primitive Neuroectodermal Tumor
Gastric primitive neuroectodermal tumor (PNET) is a very rare tumor. There are only a few case reports in the literature. Although cases with FDG uptake in the portal venous tumor thrombus (PVTT) in different primary malignancies have been evaluated before, the coexistence of PNET and PVTT has not been reported yet. Herein, we report the case of a gastric PNET with PVTT, which resolved after 3 cycles of polychemotherapy except for a residual tumor focus in the gastric corpus.
- 1 January 2013
- Published by Marmara University in Marmara Medical Journal
Is Diffuse Gastric Hypermetabolism Enough To Exclude Gastric Tumour
- 1 January 2013
- Published by Marmara University in Marmara Medical Journal
Is Diffuse Gastric Hypermetabolism Enough To Exclude Gastric Tumour
- 1 April 2012
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 37 (4) , 380-381
99mTc-MDP- and 18F-FDG-Avid Metastatic Liver Lesion
- 1 April 2012
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 37 (4) , 380-381
99mTc-MDP- and 18F-FDG-Avid Metastatic Liver Lesion